Healthcare >> CEO Interviews >> April 18, 2014
Glenn R. Mattes was appointed to serve as President, Chief Executive Officer and Director of Arno Therapeutics, Inc., in April 2011. From 2002 to 2011, Mr. Mattes served as the President of Tibotec Therapeutics, a Johnson & Johnson operating company focused on oncology and virology therapeutics. In 2008, Mr. Mattes was appointed to the President’s Advisory Council on HIV/AIDS, PACHA. Prior to Tibotec, from 1998 to 2002, Mr. Mattes served as the Vice President of Worldwide Commercial Operations at Centocor, where he played a critical role in defining Centocor’s overall business direction, as well as developing and implementing the organization’s sales and marketing strategy leading to the introduction of Remicade. Prior to joining Centocor, Mr. Mattes held positions of increasing responsibility at Rhone-Poulenc Rorer, RPR — now Aventis — including President of RPR Canada, and General Manager/Vice President of Advanced Therapeutics and Oncology, North America. Profile
Mr. Mattes: We are a clinical-stage biotechnology company focusing on specifically targeted therapies in oncology —
